ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,023.97
-1.37%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.6025
-0.05%
Brent Oil
83.76
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Revelation Biosciences Inc (REVB)

  7. Revelation Biosciences Inc (REVB) ニュース

REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:REVB
日付受信時刻ニュースソース見出しコード企業名
2024/05/1105 : 52Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/03/2305 : 15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023NASDAQ:REVBRevelation Biosciences Inc
2024/03/1322 : 00Business WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/03/1222 : 00Business WireRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceNASDAQ:REVBRevelation Biosciences Inc
2024/03/0423 : 00Business WireRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
2024/02/1410 : 12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/02/1323 : 00Business WireRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/02/1300 : 19Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/02/0906 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/02/0606 : 41Business WireRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
2024/02/0306 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:REVBRevelation Biosciences Inc
2024/02/0120 : 00Business WireRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
2024/02/0114 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
2024/01/3107 : 21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/01/3105 : 32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/01/3023 : 00Business WireRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/01/3007 : 32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/01/2406 : 18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/01/2323 : 00Business WireRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/01/2306 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2023/12/2307 : 06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:REVBRevelation Biosciences Inc
2023/12/2303 : 23Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
2023/12/1306 : 59Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:REVBRevelation Biosciences Inc
2023/11/1406 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2023/11/1406 : 05Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023NASDAQ:REVBRevelation Biosciences Inc
2023/11/1006 : 07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REVBRevelation Biosciences Inc
2023/10/1305 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2023/10/1222 : 00Business WireGemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical StudiesNASDAQ:REVBRevelation Biosciences Inc
2023/10/0422 : 00Business WireRevelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities ConferenceNASDAQ:REVBRevelation Biosciences Inc
2023/10/0305 : 24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:REVB

最近閲覧した銘柄

EU
IACUV
AMUNDI ACUV INAV
BIT
P1NEV2
BNP Paribas Issuance
NASDAQ
BYND
Beyond Meat
COIN
PGUST
PEGO NETWORK
BIT
UB63JS
Unicredit Bank
BIT
P1Q3F6
BNP Paribas Issuance
BIT
F15274
Vontobel Financial Produ...
BIT
F32840
Vontobel Financial Produ...
BIT
P1M6J5
BNP Paribas Issuance
BIT
P150T8
BNP Paribas Issuance
COIN
EQXETH
EQIFi Token
NASDAQ
FIAMX
Fidelity Advisor Sustain...
TSX
MCB
McCoy Global
COIN
NBNGETH
NOBUNAGA
BTHB
WIKENKRW
ProjectWITH
BIT
P1U241
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有